Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.
UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.
Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.
Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.
Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.
Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.
Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.
Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.
Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.
Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.
Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.
Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.
Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.
In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.
April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.
Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.
Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.
The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.
Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.
Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.
Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.
James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.
Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.
Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.
Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.